InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-39.2%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Walbert Keli, Director. Director active across 2 companies, notably Apellis Pharmaceuticals, Inc.. In total, 3 disclosures have been logged. Activity tracked since 8 January 2025. The latest transaction was disclosed on 8 January 2025 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Declarations3 total
17,051 sharesCommon StockSEC:0001193125-26-224601
17,051 sharesCommon StockSEC:0001193125-26-224601:0
9,090 shares0Common StockSEC:0001127602-25-001073:0
3 of 3 declarations
About Walbert Keli
Keli Walbert is a Board Member at Apellis Pharmaceuticals, Inc. She brings significant expertise in corporate governance and strategy. In her role, Keli oversees operations and contributes to strategic decision-making for the company. Her experience in the pharmaceutical sector is an asset for Apellis.
